Research programme: anti-ganglioside antibody - Arana

Drug Profile

Research programme: anti-ganglioside antibody - Arana

Alternative Names: ART150; CEP-37249; DMF10; EGX-150

Latest Information Update: 17 Oct 2011

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator University of Massachusetts Medical School
  • Developer Cephalon
  • Class Antineoplastics; Monoclonal antibodies
  • Mechanism of Action Ganglioside inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Lung cancer; Malignant melanoma

Most Recent Events

  • 14 Oct 2011 Cephalon has been acquired by Teva Pharmaceutical Industries
  • 10 Aug 2009 Arana Therapeutics has been acquired by Cephalon
  • 16 Mar 2009 Preclinical development is ongoing in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top